Beckman’s SARS-CoV-2 IgM antibody test gets EUA
Oct. 12, 2020—Beckman Coulter announced its Access SARS-CoV-2 immunoglobulin M assay has received emergency use authorization from the FDA.
Webinars and Sponsored Roundtables — Register Now
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
GenMark ePlex Respiratory Pathogen Panel 2 receives EUA
Oct. 9, 2020—GenMark Diagnostics received FDA emergency use authorization for its ePlex Respiratory Pathogen Panel 2.
Aptima SARS-CoV-2 assay to include testing of asymptomatic people
Oct. 7, 2020—Hologic’s Aptima SARS-CoV-2 assay, which initially received emergency use authorization from the FDA in May, is now authorized for testing people without symptoms or other reasons to suspect COVID-19 infection.
CompuGroup Medical hosts virtual user conference
Oct. 6, 2020—CompuGroup Medical US will hold its annual CGM LABDAQ User Conference virtually, starting Oct. 6.
Beckman Coulter Access IL-6 test gets EUA
Oct. 6, 2020—Beckman Coulter has received emergency use authorization for its Access Interleukin-6 assay from the FDA.
Cepheid SARS-CoV-2, flu A/B, RSV test gets EUA
Oct. 5, 2020—Cepheid received emergency use authorization from the FDA for its Xpert Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic test for qualitative detection of the viruses that cause COVID-19, flu A, flu B, and RSV infections from a single patient sample.
Technopath introduces QC data management solution
Oct. 2, 2020—Technopath Clinical Diagnostics introduced IAMQC Infinity for the management of overall quality control and proficiency testing.
FDA approves liquid biopsy NGS CDx
Oct. 1, 2020—The FDA approved the Guardant360 CDx assay (Guardant Health), a liquid biopsy companion diagnostic that also uses next-generation sequencing technology to identify patients with specific types of mutations of the epidermal growth factor receptor gene in a deadly form of metastatic non-small cell lung cancer.
Siemens, CDC to develop process to standardize SARS-CoV-2 assays
Sept. 29, 2020—Siemens Healthineers will collaborate with the Centers for Disease Control and Prevention and the Joint Research Centre of the European Commission on a research project to develop a novel process for standardizing SARS-CoV-2 assays.
FDA issues EUA for Yale’s SalivaDirect
Sept. 28, 2020—The FDA issued an emergency use authorization to Yale School of Public Health for its SalivaDirect COVID-19 diagnostic test, which uses a new method of processing saliva samples when testing for COVID-19 infection, the agency says.